



# **IMMUCELL CORP /DE/**

## **FORM 8-K**

(Current Report Filing)

Filed 04/09/24 for the Period Ending 04/09/24

Address 56 EVERGREEN DR, PORTLAND, ME, 04103  
Telephone (727) 384-2323  
CIK 0000811641  
Symbol ICCC  
SIC Code 2835 - In Vitro & In Vivo Diagnostic Substances  
Fiscal Year 12/31

Powered by **barchart**

<https://www.barchart.com/solutions>

© Copyright 2022, Barchart.com, Inc. All Rights Reserved.

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) April 9, 2024

**ImmuCell Corporation**

(Exact name of registrant as specified in its charter)

DE  
(State or other jurisdiction  
of incorporation)

001-12934  
(Commission File Number)

01-0382980  
(IRS Employer  
Identification No.)

56 Evergreen Drive Portland, Maine  
(Address of principal executive offices)

04103  
(Zip Code)

Registrant's telephone number, including area code 207-878-2770

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common Stock, \$0.10 par value per share	ICCC	The NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 2.02. Results of Operations and Financial Condition**

On April 9, 2024 ImmuCell Corporation (the "Company") issued a press release announcing its unaudited product sales for the three-month period ended March 31, 2024. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:

99.1 [Press Release of ImmuCell Corporation dated April 9, 2024.](#)

---

1

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**IMMUCELL CORPORATION**

Date: April 9, 2024

By: /s/ Michael F. Brigham  
Michael F. Brigham  
President, Chief Executive Officer and Principal  
Financial Officer

---

2

---

**Exhibit Index**

<b>Exhibit No.</b>	<b>Description</b>
99.1	<a href="#">Press Release of ImmuCell Corporation dated April 9, 2024.</a>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

---

3

---